Thank you for your interest in Ash Access Technology, Inc and taking the time to visit our website!  We are excited to share our vision for our organization as well as the tremendous possibilities our product portfolio can have in the health and well-being of patients using vascular access devices.

Ash Access Technology, Inc. is committed to the development of breakthrough therapies and devices that can significantly reduce the incidence and impact of vascular access complications.  Under the leadership of Dr. Stephen Ash, the research and development at Ash Access Technology, Inc. has been focused on strategies to prevent the ever-increasing incidence of catheter-related bloodstream infection (CRBSI), improve patency of central venous catheters for dialysis (CVCD) as well as eradicate biofilm which is a dangerous safe haven for bacteria.

Vascular access complications are unfortunately far to common and cause a significant burden to patients, their families and the healthcare team providing their care.  According to the US Centers for Disease Control (CDC), the magnitude of CRBSI is an estimated 200,000 to 400,000 episodes annually.  Studies have shown the mortality rates associated with CRBSI range from 12-25% while annual healthcare costs for treating these infections may exceed $2 Billion. The growth of biofilm on catheter surfaces and the safe haven it provides is a primary cause of CRBSI.  Biofilm is very difficult to eradicate and becomes a significant barrier for successful treatment with antibiotic therapy. Thus, the healthcare industry has seen an explosion in antibiotic resistant strains of bacteria as well as a high reoccurrence of infection. In addition, poor catheter blood flow or patency leads to interrupted and unsuccessful dialysis sessions, use of expensive medications to eliminate clots or blockages and eventually to the removal of a patient’s catheter.

Our vision to address the unmet medical needs associated with the complications of vascular access devices is multifaceted.

• Development of a broad spectrum, non-antibiotic, antimicrobial / antithrombotic therapy designed to significantly reduce the incidence of CRBSI, maintain catheter patency and eradicate biofilm.
• Introduction of an innovative open and closed tip long-term hemodialysis catheter to prevent patency failures by allowing optimum flow during dialysis and the retention of any catheter therapies between dialysis sessions.
• Commercialization of next generation peritoneal catheter design.
• Creation of an antimicrobial catheter impregnation system that potentially lasts for months – not days.

We hope this site provides the information you were seeking or the answer to questions you may have about our organization.  We are excited about the future and potential and impact the product portfolio we are creating at Ash Access Technology, Inc. can have in the lives of patients requiring vascular access and for the medical community providing their care.  If you would like more information or have additional questions please contact us.

Sincerely yours,

Robert B. Truitt
President and CEO